血浆同型半胱氨酸和血清叶酸、维生素B12检测及其在糖尿病肾病中的临床意义

应用荧光偏振免疫分析法和时间分辨荧光免疫分析法分别测定血浆同型半胱氨酸(homocysteine,Hcy)和血清叶酸(FA)、维生素B12(VitB12)的水平,探讨其在糖尿病肾病(diabetic nephropathy,DN)中的临床价值。选择137例糖尿病(DM)患者,并根据尿微量白蛋白(uMA)的排泄率及血肌酐(SCr)水平将其分为糖尿病无肾病组、DN初期组、临床DN组和氮质血症组,同时测定以40名健康人作对照组,检测其Hcy、FA和VitB12。采用SPSS10.0统计软件,进行直线回归相关分析。结果显示:四组DM患者血浆Hcy水平分别与对照组比较均显著性增高(P<0.05~0.01),并随DN患者肾脏损伤程度的加重而升高,每两组间相比有显著性差异(P<0.01)。四组DM患者血清FA、VitB12水平分别与对照组比较,除糖尿病无肾病组无显著性差异(P>0.05)外,其余三组均有显著性差异(P<0.01),每两组间比较均有显著性差异(P<0.01)并与血浆Hcy水平呈现负相关。结论:高Hcy血症是DM和DN患者的危险因素,血浆Hcy水平可作为DM和DN病情监测的有效指标,FA、VitB12的降低可能是诱发高Hcy血症的一个重要因素。     

下肢动脉硬化性闭塞症病人术前血清瘦素、艾帕素、内脏脂肪特异性丝氨酸蛋白酶抑制物水平与介入治疗后复发相关性

目的 探究血清瘦素、艾帕素（Apelin）、内脏脂肪特异性丝氨酸蛋白酶抑制物（Vaspin）水平对下肢动脉硬化性闭塞症（ASO）病人介入治疗后复发风险的预测价值。方法 选取2014年12月至2017年12月西安市第九医院收治的因ASO行介入治疗病人120例作为研究对象,根据术后复发情况分为复发组39例和无复发组81例。采用酶联免疫吸附测定检测病人术前血清瘦素、艾帕素、Vaspin水平;采用logistic回归模型分析ASO病人介入治疗后复发的影响因素;受试者操作特征曲线（ROC曲线）分析血清瘦素、艾帕素、Vaspin水平对ASO病人介入治疗后复发的预测价值。结果 复发组合并糖尿病比例、完全闭塞病变比例、单纯行球囊扩张术比例、血管病变长度显著高于无复发组（P<0.05）;复发组术前血清瘦素（9.48±2.03）μg/L水平显著高于无复发组（5.01±1.54）μg/L,血清艾帕素（1.19±0.34）μg/L、Vaspin(0.31±0.17)μg/L水平显著低于无复发组（1.76±0.62）μg/L、（0.43±0.12）μg/L(P<0.05)。与未合并糖尿病、血管病变长...     

白细胞介素12基因修饰的Lewis肺癌瘤苗的抗肿瘤免疫作用

目的：研究白细胞介素12（IL-12）基因修饰的Lewis肺癌瘤苗的抗肿瘤免疫作用。方法：用含IL-12基因的腺病毒载体,在体外以不同感染系数感染Lewis肺癌细胞,并分别接种于C57BL/6小鼠皮下,观察其致瘤性的变化;并用Lewis肺癌细胞及B16黑色素瘤细胞再 次攻击免疫后的C57BL/6小鼠,观察肿瘤发生情况。 结果：以各种感染系数AdCMVIL-12制备的瘤苗,接种于小鼠皮下后,无肿瘤生长,完全消除了Lewis肺癌细胞的致瘤性;瘤苗注射6 d后,用Lewis肺癌细胞再次攻击,仍无肿瘤生长,抑瘤率达100%;用B16黑色素瘤细胞攻击,10~12 d均有肿瘤生长,说明此瘤苗具有肿瘤特异性。结论：AdCMVIL-12能消除Lewis肺癌细胞的致瘤性,并能诱导显著的抗肿瘤免疫反应,对肿 瘤的复发及转移有较好疗效。     

口服小分子抗新型冠状病毒药物的研究进展

新型冠状病毒肺炎是由严重急性呼吸道综合征冠状病毒2引起的急性呼吸道传染病,是近百年来人类遭遇的影响范围最广的全球性大流行疾病。抗病毒药物是治疗新型冠状病毒感染的首选。口服小分子抗新型冠状病毒药物使用方便,且适用于轻中症患者。目前小分子抗新型冠状病毒药物有血管紧张素转换酶2(ACE2)抑制剂、膜融合抑制剂、RNA聚合酶抑制剂和3CL蛋白酶抑制剂。归纳了口服小分子抗新型冠状病毒药物的研究进展,为口服小分子抗新型冠状病毒药物的研发提供思路。     

泛素特异性蛋白酶2、微RNA-432-5p在食管癌组织中表达及临床意义

目的 探讨食管癌组织泛素特异性蛋白酶2(USP2)、微RNA-432-5p(miR-432-5p)的表达及临床意义。方法 选取2014年6月至2016年6月在辽宁省肿瘤医院接受外科手术治疗的93例食管癌病人作为研究对象,取手术切除的食管癌组织及其癌旁组织,采用免疫组织化学法检测USP2的表达情况,采用实时荧光定量PCR(qRT-PCR)法检测组织中USP2 mRNA、miR-432-5p表达水平,以食管癌组织中miR-432-5p表达水平平均数分为miR-432-5p低表达组和miR-432-5p高表达组,分析食管癌组织USP2、miR-432-5p表达与食管癌病人临床病理特征的关系;使用生物信息学Targetscan网站搜索USP2、miR-432-5p是否存在结合位点,进一步分析食管癌组织USP2、miR-432-5p的相关性;采用Kaplan-Meier法分析USP2、miR-432-5p表达与食管癌病人预后的关系。结果 食管癌组织中USP2 mRNA表达水平(2.53±0.71比1.05±0.36)、USP2阳性率(55.91%比6.45%)明显高于癌旁组织(P<0.05...     

Effect of grouped ST36 or RN12 on gastric motility andsensation

Objective: To investigate the effects of paired ST36 and RN12 acupuncture stimulation on gastric motility and the firing rate of responsible neurons in anesthetized rats.Methods: Using electrophysiological methods, we measured the effects of acupuncture at RN12, ST36, or RN12+ST36 on gastric motility as well as nerve discharges from the gastric sympathetic, vagal nerve, and wide dynamic range(WDR) neurons in the spinal dorsal horn T7-9 in anesthetized rats.Results: 1) Acupuncture at RN12 inhibited gastric motility(83.84±4.49)% and vagal nerve discharge(65.64±5.67)%, but promoted sympathetic nerve activity(243.70±40.67)%; acupuncture at ST36 induced opposing effects on gastric motility(111.31±2.01)% and vagal nerve discharge(166.98±15.92)%. Interestingly, acupuncture at RN12+ST36 together yielded effects similar to that of acupuncture at RN12 alone(93.59±2.05)%,(54.52±7.12)%. 2) WDR neuron discharges induced by gastric distension were inhibited by acupuncture at RN12(194.56 ±18.79)%. However, acupuncture at ST36 induced a more significant inhibitory effect.Conclusion: Acupuncture at RN12 inhibits gastric motility by activation of the sympathetic reflex at the spinal level; acupuncture at ST36 promotes gastric motility by activation of the parasympathetic reflex at the supraspinal level, and acupuncture at RN12+ST36 produces a similar decrease in gastric motility as RN12 stimulation alone. Both acupoints decrease the effect of noxious gastric distention on WDR neuron activity, but paired RN12+ST36 stimulation does not significantly affect WDR neuron discharge.     

SETD4对脂多糖诱导的AML12细胞IL-6转录的调控作用

目的　探讨SETD4（SET-domain containing protein 4）对脂多糖（LPS）诱导的AML12（小鼠肝脏细胞系）细胞IL-6的转录调控作用。 方法　构建SETD4表达质粒和IL-6 启动子荧光素酶报告基因质粒,共转染小鼠肝脏细胞系AML12,使用双荧光素酶报告基因技术检测LPS刺激后IL-6 启动子荧光素酶活性;单独转染SETD4表达质粒上调AML12细胞SETD4表达,检测LPS刺激后IL-6 mRNA水平变化。 结果　双酶切鉴定及核酸测序证实重组质粒pcDNA3.0/HA-SETD4、pGL3.0/IL-6 promoter的构建成功。pcDNA3.0/HA-SETD4与pGL3.0/IL-6 promoter共转染AML12细胞,LPS刺激后SETD4对IL-6 启动子荧光素酶活性没有影响;上调SETD4表达后,可以促进LPS诱导的IL-6 mRNA转录。 结论　成功构建SETD4真核表达质粒和IL-6启动子荧光素酶报告基因质粒;SETD4对LPS诱导的AML12细胞IL-6的转录发挥正调控作用。     

Chromosome 17q12 duplications: Further delineation of the range of psychiatric and clinical phenotypes

Copy number variants at chromosome 17q12 have been associated with a spectrum of phenotypes. Deletions of 17q12 are well described and associated with maturity onset diabetes of the young type 5 (MODY5) and cystic renal disease (HNF1β) as well as cognitive impairment and seizures. Duplication of 17q12 is emerging as a new genetic syndrome, associated with learning disability, seizures, and behavioral problems. The duplication is often inherited from an apparently unaffected parent. Here, we describe a three‐generation family with multiple individuals carrying a17q12 microduplication with varying clinical features, consistent with variable penetrance. The proband who inherited a 1.8 Mb interstitial 17q12 duplication from his mother presented with developmental delay, behavioral problems, and mild dysmorphism. One of his sisters, his maternal uncle, and his maternal grandmother also carry the 17q12 microduplication. Clinical features of the carriers include renal problems, diabetes mellitus, learning difficulties, epilepsy and mental illness. Cognitive abilities range from normal function to moderate impairment (full‐scale IQ range: 52‐99). In light of recent reports of association of this locus with schizophrenia, we performed a detailed psychiatric assessment and confirmed that one family member has symptoms consistent with a diagnosis of schizophrenia and another has a prodromal syndrome with attenuated positive symptoms of psychosis. This report extends the clinical phenotype associated with the 17q12 microduplication and highlights the phenotypic variability.     

The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis

Introduction: Psoriasis is a common, immune-mediated skin disease often associated with significant physical and psychosocial impairment. Antipsoriatic biologic agents offer patients unparalleled treatment potential in regard to greater skin clearance and overall improved quality of life. Evaluation of the therapeutic efficacy of biologic agents on the full psoriasis disease burden must account for their impact on both physical symptoms, as well as patient-reported, health-related quality of life (HRQoL) measurements.

Areas covered: Results from numerous clinical trials demonstrate the significant clinical efficacy of biological agents targeting tumor necrosis factor-α (TNF-α) and the interleukin (IL)-12/23 and IL-17 immune pathways. However, relatively limited data is available evaluating their full effect on quality of life outcomes. This review will discuss the most relevant and up-to-date clinical data on HRQoL measurements related to treatment with these aforementioned biologic agents.

Expert commentary: Patient-reported outcomes (i.e. Dermatology Life Quality Index) are being used with increasing frequency in clinical trials, and provide valuable information on the impact of psoriasis on numerous aspects of day-to-day living. These outcomes must also be incorporated in clinical practice, in addition to physical assessment of disease severity, treatment decisions, and therapeutic response in the psoriasis patient population.